Drug intelligence / Profile preview

COVID-EIG

Development stage: Unknown
Lead developer: Emergent BioSolutions
Modality: Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**COVID-EIG** is an investigational plasma-derived therapy developed by Emergent BioSolutions using equine plasma from horses immunized against SARS-CoV-2. It is a hyperimmune globulin product designed to provide passive immunity through neutralizing antibodies for the potential treatment or prevention of COVID-19, particularly in high-risk or hospitalized patients. Emergent is developing it alongside the human plasma-derived counterpart COVID-HIG, with plans for clinical trials in various patient populations.

Other names: COVID-Equine Immune Globulin

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on COVID-EIG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-EIG.

Explore the full profile